Cogitum

Cogitum is the proprietary pharmaceutical preparation of potassium N-acetyl-DL-aminosuccinate (bipotassium acetylaminosuccinate), a synthetic analog of N-acetylaspartate (NAA), the most concentrated free amino acid derivative in the mammalian central nervous system. The compound was developed in France and patented in the United States in 1969 (US 3,433,875) for the improvement of mental performance in adults experiencing intellectual overwork, memory disorders, and cognitive decline associated with senescence. The active substance provides an exogenous source of the acetylated aspartate moiety that participates in neuronal energy metabolism through the tricarboxylic acid cycle, serves as the obligate precursor for myelin lipid synthesis via oligodendrocytic aspartoacylase-mediated deacetylation, functions as an osmolyte maintaining neuronal volume homeostasis, and is the direct biosynthetic precursor of N-acetylaspartylglutamate (NAAG), the most abundant neuropeptide in the human brain and an endogenous agonist at the presynaptic metabotropic glutamate receptor type 3 (mGluR3). Cogitum is classified pharmacologically as a tonic agent and adaptogen; it is registered and marketed as a drinkable oral solution (250 mg per 10 mL ampoule) in France, Portugal, and several other jurisdictions, and is used extensively in Russian neuropediatric practice for the treatment of asthenic syndrome, attention deficit hyperactivity disorder with subclinical epileptiform activity, speech and language delay, and neurodevelopmental disorders in children aged seven years and older.

The clinical evidence base includes a 2023 double-blind, randomized, placebo-controlled trial demonstrating that potassium N-acetylaminosuccinate at 750 mg for 21 days significantly reduced fatigue scores and improved complex cognitive functions in adults with asthenic syndrome compared to placebo, with no reported adverse events (Esin et al., 2023). Pediatric evidence comprises a 249-patient study in children with ADHD and subclinical epileptiform electroencephalographic activity demonstrating significant improvements in attention, memory, and speech without aggravation of epileptiform discharges or provocation of seizures; additional cohort studies in children with speech delay, traumatic brain injury sequelae, mental retardation, and schizotypal spectrum disorders have reported efficacy in improving cognitive and linguistic performance. The pharmacological rationale rests on the established neurobiology of endogenous N-acetylaspartate: NAA concentrations in the brain reach 10 millimolar or greater, are confined almost exclusively to neurons, and serve as the principal magnetic resonance spectroscopy marker of neuronal viability; reduced NAA is a consistent finding in neurodegenerative disease, traumatic brain injury, multiple sclerosis, and neurodevelopmental disorders. The exogenous provision of the acetylaminosuccinate moiety is hypothesized to support neuronal mitochondrial energy production, to provide acetate substrate for oligodendrocytic myelin lipid synthesis, and to augment NAAG-mediated glutamatergic neuromodulation.

Safety data across pediatric and adult populations demonstrate excellent tolerability. The compound has no reported cases of overdose toxicity, produces no clinically significant drug interactions at registered doses, and is contraindicated only in cases of known hypersensitivity to the active substance or excipients. The principal limitation of the evidence base is the concentration of clinical research in Russian-language journals with limited replication in Western multicenter trial frameworks. This monograph documents the chemistry, synthesis, mechanism, pharmacokinetics, clinical evidence, sourcing, reconstitution, stack interactions, adverse events, and comparative assessment of Cogitum against five neurometabolic and nootropic alternatives on five competency standards.